Back to Stakeholders
Categories

1 domain / 2 areas / 2 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Psychedelic Healthcare ImplementationHealth EconomistsPayer & Reimbursement Stakeholders

Institute for Clinical and Economic Review (ICER)

U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

HTA / Value Assessment Body

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingBudget Impact AnalysisCoverage Policy Design

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget ImpactPatient-Reported Outcomes

Market Access Notes

ICER conducts independent evidence and value assessments used by U.S. payers and policy stakeholders; ICER has published a dedicated esketamine review and has also assessed MDMA-AP.

Verification

Verified

Psychedelic Focus

Explicit Psychedelic Focus

Engagement Status

Active

Primary Access Link

Source Evidence

ICER Topic - Depression: Treatment-Resistant

https://icer.org/topic/depression/

ICER Final Evidence Report - Esketamine for Treatment-Resistant Depression (2019)

https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf

Quick Facts

Website
Visit